We are live on ! Find out more
TGI

TRV GP II Portfolio holdings

AUM $1.34M
1-Year Est. Return 67.55%
This Fund
S&P 500
This Quarter Est. Return
+24.85%
1 Year Est. Return
-67.55%
3 Year Est. Return
-20.84%
5 Year Est. Return
-49.87%
10 Year Est. Return
–
AUM
$555M
AUM Growth
–
Cap. Flow
+$522M
Cap. Flow %
93.96%
Top 10 Hldgs %
100%
Holding
5
New
5
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$173M
2
JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
+$150M
3
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$111M
4
SAGE
Sage Therapeutics
SAGE
+$53.1M
5
ALNA
Allena Pharmaceuticals
ALNA
+$34.4M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BPMC
1
DELISTED
Blueprint Medicines
BPMC
$185M 33.32%
+2,453,753
New +$173M
JNCE
2
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$130M 23.49%
+10,230,349
New +$150M
MYOK
3
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$121M 21.87%
+2,885,104
New +$111M
SAGE
4
DELISTED
Sage Therapeutics
SAGE
$90.2M 16.25%
+547,916
New +$53.1M
ALNA
5
DELISTED
Allena Pharmaceuticals
ALNA
$28.1M 5.06%
+2,790,964
New +$34.4M

Similar funds

IVAV
Index Venture Associates V St. Helier, Channel Islands, Jersey $1.46M AUM 88.05% 1-Year Est. Return
VM
Value Monitoring Menlo Park, California $1.5M AUM 13.21% 1-Year Est. Return
CL
CRV LLC Palo Alto, California $1.56M AUM 87.36% 1-Year Est. Return
GAM
GVO Asset Management Zug, Switzerland $1.07M AUM 24.36% 1-Year Est. Return
MC
Manteio Capital Jersey City, New Jersey $1.05M AUM
NC
Noked Capital Tel Aviv, Israel $946K AUM 17.1% 1-Year Est. Return
HCIG
H Capital II GP Grand Cayman, Cayman Islands $1.83M AUM
NP
Nimble Partners San Francisco, California $556K AUM 61.7% 1-Year Est. Return

TRV GP II's Q4 2017 Portfolio in Review

Q4 2017 is the first quarter with a 13F filing on record for TRV GP II, which disclosed 5 positions worth $555M. Its ten largest holdings account for 100% of the portfolio.

Its largest position is Blueprint Medicines: 2,453,753 shares worth $185M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets.

  • TRV GP II's largest Q4 2017 buy was Blueprint Medicines: 2,453,753 shares worth $185M.
  • TRV GP II's ten largest holdings make up 100% of its $555M portfolio in Q4 2017.
  • TRV GP II disclosed 5 positions in Q4 2017, its first 13F filing on record.

Based on TRV GP II's 13F filing for Q4 2017, filed 13 Feb 2018.